Hanmi's BH3120 Immunotherapy Advances in Trials
Hanmi's BH3120 dual-antibody shows safety and efficacy in early trials for advanced solid tumors.
Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical recently presented progress on BH3120, their innovative immunotherapy, at the Society for Immunotherapy of Cancer (SITC) conference in Houston, USA. BH3120, developed using Hanmi's "Pentambody" dual-antibody platform, targets PD-L1 on cancer cells and 4-1BB on immune cells, enhancing immune responses against tumors.
Preclinical studies showed significant anticancer efficacy and minimized side effects. Currently, a Phase 1 trial in South Korea and the U.S. demonstrates promising safety and tolerability in advanced solid tumor patients, advancing through dose escalation with no major toxicities reported.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix
Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park
Discussion